Forecasting The Future: 6 Analyst Projections For bluebird bio
Portfolio Pulse from Benzinga Insights
bluebird bio (NASDAQ:BLUE) was analyzed by 6 analysts, showing a shift towards a more bearish outlook over the last 30 days. The average 12-month price target is now $6.17, down 20.08% from the previous average, with a high estimate of $12.00 and a low of $1.02. Analysts from firms including HSBC, B of A Securities, Wells Fargo, Baird, and Morgan Stanley have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. bluebird bio's financials indicate strong revenue growth but challenges in profitability, asset utilization, and debt management.
March 05, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
bluebird bio's stock outlook has become more bearish according to 6 analysts, with a new average price target of $6.17. Despite strong revenue growth, profitability and debt management pose challenges.
The bearish shift in analyst sentiment, evidenced by lowered price targets and concerns over profitability and debt management, suggests a negative short-term impact on BLUE's stock price. The significant revenue growth is a positive factor, but the challenges in profitability and high debt levels are likely to weigh more heavily on investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100